Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15285632 | 0.93 | HCRTR2 (0.42) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL29713169 | 0.93 | HCRTR2 (0.42) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL7591113 | 0.91 | EPHX1 (0.43) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL16846897 | 0.89 | HCRTR2 (0.45) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL20980330 | 0.85 | HCRTR2 (0.40) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL14690510 | 0.84 | HCRTR2 (0.44) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL16846705 | 0.82 | HCRTR2 (0.43) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL14704752 | 0.82 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL31432022 | 0.81 | HCRTR2 (0.41) | HCRTR2TDP1MAOAMAOBMEN1 | |
| SCHEMBL27343898 | 0.81 | HCRTR2 (0.41) | HCRTR2TDP1MAOAMAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220251116-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-08-11 | — | — | US | disclosed |
| US-20200325161-A1 | HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| US-20200325161-A1 | HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20150329539-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329539-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2014099586-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HCRTR2 4673/4885TDP1 2111/4885MAOA 2505/4885 |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, REV1 | HCRTR2 2851/4885TDP1 218/4885MAOA 1240/4885 |
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | ARG1, ARG2, PRMT1 | HCRTR2 519/4885TDP1 494/4885MAOA 169/4885 |
| US-20220251116-A1 | ALKYLBORONIC ACIDS AS ARGINASE INHIBITORS | ARG1, ARG2, PADI6 | HCRTR2 1319/4885TDP1 493/4885MAOA 242/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | HCRTR2 3274/4885TDP1 619/4885MAOA 3101/4885 |
| US-20200325161-A1 | HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS | ARG1, ARG2, PRMT1 | HCRTR2 519/4885TDP1 494/4885MAOA 169/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HCRTR2 4687/4885TDP1 2117/4885MAOA 2610/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | HCRTR2 4671/4885TDP1 3816/4885MAOA 2063/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | HCRTR2 4623/4885TDP1 2206/4885MAOA 3284/4885 |
| US-20150329539-A1 | 4-PYRIDINONETRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS | TYMP, TYMS, PNPO | HCRTR2 4024/4885TDP1 47/4885MAOA 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.